ASLAN Pharmaceuticals Limited (ASLN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ASLN Stock Price Chart Interactive Chart >
ASLN Price/Volume Stats
| Current price | $0.39 | 52-week high | $3.87 |
| Prev. close | $0.39 | 52-week low | $0.38 |
| Day low | $0.39 | Volume | 306,500 |
| Day high | $0.42 | Avg. volume | 194,811 |
| 50-day MA | $0.68 | Dividend yield | N/A |
| 200-day MA | $1.36 | Market Cap | 27.42M |
ASLAN Pharmaceuticals Limited (ASLN) Company Bio
ASLAN Pharmaceuticals Pte. Ltd., a biotechnology company, develops immuno-oncology agents and targeted therapies. It offers ASLAN001, a pan-HER inhibitor for solid tumours; and ASLAN002, a cMET inhibitor for solid tumours. The company also inlicenses preclinical and early clinical/development compounds and candidate drugs from pharmaceutical companies focusing on oncology, respiratory, and inflammation diseases; gets proof of concept (PoC) for the partnered compounds in Asia; and outlicenses PoC compounds back to partner for development and launch. It sells its products in Asia and internationally. ASLAN Pharmaceuticals Pte. Ltd. was founded in 2010 and is based in Singapore.
Latest ASLN News From Around the Web
Below are the latest news stories about ASLAN Pharmaceuticals Ltd that investors may wish to consider to help them evaluate ASLN as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: BioDelivery (BDSI), Aslan Pharmaceuticals (ASLN) and Compass Therapeutics (CMPX)Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioDelivery (BDSI – Research Report), Aslan Pharmaceuticals (ASLN – Research Report) and Compass Therapeutics (CMPX – Research Report). BioDelivery (BDSI) H.C. Wainwright analyst Oren Livnat maintained a Hold rating on BioDelivery today and set a price target of $4.50. The company's shares closed last Thursday at $3.18. According to TipRanks. |
ASLAN (ASLN) Starts Phase IIb Study in Atopic DermatitisASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis. |
Aslan Pharmaceuticals begins phase2b study of ASLAN004 for eczemaAslan Pharmaceuticals (ASLN) screened the first patient in its phase 2b dose-ranging study of eblasakimab in adults with moderate-to-severe atopic dermatitis ((AD)), also |
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic DermatitisThe TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptorThis dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimensTopline results are expected in 1H 2023 MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused bioph |
ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004- Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the second episode in its series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and |
ASLN Price Returns
| 1-mo | -41.85% |
| 3-mo | -55.58% |
| 6-mo | -73.65% |
| 1-year | -86.87% |
| 3-year | -88.19% |
| 5-year | N/A |
| YTD | -65.18% |
| 2021 | -38.80% |
| 2020 | -9.85% |
| 2019 | -43.61% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...